WebJun 13, 2005 · Generic Name. Bivalirudin. DrugBank Accession Number. DB00006. Background. Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered … WebBivalirudin Bolus: None Continuous infusion: Normal organ function → 0.15 mg/ kg/h Renal or liver dysfunction → dose reduction may be appropriate Adjust to APTT ... Heparin Re-Exposure in Patients with a History of HIT CARDIAC AND VASCULAR SURGERY In patients with a history of HIT, HIT laboratory testing may be used to ...
Bivalirudin - UpToDate
WebIn in vitrostudies, bivalirudin exhibited no platelet aggregation response against sera from patients with a history of HIT/HITTS. Among 494 subjects who received bivalirudin in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests. Neither subject WebDec 10, 2024 · In the pooled data, bivalirudin was associated with a reduction in serious bleeding rates compared with heparin and, in the STEMI subgroup, a 30-day mortality … small urpower humidifier
Heparin-induced thrombocytopenia Guideline - UI Health Care
WebJun 30, 2024 · In recent years, much progress has been made in the field of antithrombotic drugs in acute coronary syndrome (ACS) treatment, as reflected by the introduction of the more potent P2Y12-inhibitors prasugrel and ticagrelor, and novel forms of concomitant anticoagulation, such as fondaparinux and bivalirudin. However, despite substantial … WebMar 12, 2024 · The efficacy and safety of bivalirudin in percutaneous coronary intervention (PCI) has always been a hot topic in perioperative antithrombotic therapy, but there are still some controversies. ... anemia, myocardial-infarction history, PCI history, moderate-to-severe renal-impairment, gastrointestinal-bleeding history in the … WebMay 10, 2024 · Argatroban and Bivalirudin (Angiomax®) o There is no FDA-approved reversal agent for Argatroban or Bivalirudin o Reversal agent is likely not needed if 3 – 5 half-lives have elapsed o Argatroban half-life 40 - 50 minutes o Bivalirudin half-life 25 minutes, extended up to 3.5 hour in patients on dialysis o hik connect apk android